Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation

BACKGROUND AND PURPOSE: Targeted therapy and immunotherapy have led to dramatic change in the treatment of lung cancer, however, the overall 5-year survival rate of lung cancer patients is still suboptimal. It is important to exploit new potential of molecularly targeted therapies. High-frequency so...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Meiling, Li, Yan, Ye, Xiaoping, Zhang, Linlin, Wang, Zhifang, Xu, Xiaowen, Shen, Yejing, Zheng, Cuixia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310414/
https://www.ncbi.nlm.nih.gov/pubmed/32576270
http://dx.doi.org/10.1186/s12964-020-00568-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310414/
https://www.ncbi.nlm.nih.gov/pubmed/32576270
http://dx.doi.org/10.1186/s12964-020-00568-z

Ejemplares similares